Leerink upgraded Cryoport (CYRX) to Outperform from Market Perform with a price target of $16, up from $10. The firm believes the company is positioned to beat estimates on continued cell and gene therapy market services strength. The analyst is also encouraged by recent stabilization in the company’s MVE business. Leerink sees “beats and raises” well into 2026 for Cryoport.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX: